[go: up one dir, main page]

MX2022009860A - Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion. - Google Patents

Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion.

Info

Publication number
MX2022009860A
MX2022009860A MX2022009860A MX2022009860A MX2022009860A MX 2022009860 A MX2022009860 A MX 2022009860A MX 2022009860 A MX2022009860 A MX 2022009860A MX 2022009860 A MX2022009860 A MX 2022009860A MX 2022009860 A MX2022009860 A MX 2022009860A
Authority
MX
Mexico
Prior art keywords
polypeptides
infection
treat
compositions
limit development
Prior art date
Application number
MX2022009860A
Other languages
English (en)
Inventor
Neil P King
Carl Walkey
David Veesler
Alexandra C Walls
Jing Yang Wang
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2022009860A publication Critical patent/MX2022009860A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente descripción se describen polipéptidos que comprenden una secuencia de aminoácidos al menos 95 %, al menos 96 %, al menos 97 %, al menos 98 %, al menos 99 % o al menos 100 % idéntica a la secuencia de aminoácidos seleccionada del grupo que consiste en SEQ ID NOS:1-84, 138-146 y 167-184, nanopartículas de los mismos, composiciones de nanopartículas relacionadas y su uso para tratar o limitar el desarrollo de una infección.
MX2022009860A 2020-02-14 2021-02-12 Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion. MX2022009860A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062977036P 2020-02-14 2020-02-14
US202063046159P 2020-06-30 2020-06-30
US202063064235P 2020-08-11 2020-08-11
PCT/US2021/017799 WO2021163438A1 (en) 2020-02-14 2021-02-12 Polypeptides, compositions, and their use to treat or limit development of an infection

Publications (1)

Publication Number Publication Date
MX2022009860A true MX2022009860A (es) 2022-11-07

Family

ID=74873805

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009860A MX2022009860A (es) 2020-02-14 2021-02-12 Polipeptidos, composiciones y su uso para tratar o limitar el desarrollo de una infeccion.

Country Status (13)

Country Link
US (1) US20240277831A1 (es)
EP (1) EP4103230A1 (es)
JP (1) JP2023513720A (es)
KR (1) KR20220142472A (es)
CN (1) CN116096404A (es)
AU (1) AU2021221139A1 (es)
BR (1) BR112022016220A2 (es)
CA (1) CA3167318A1 (es)
CO (1) CO2022011467A2 (es)
MX (1) MX2022009860A (es)
PE (1) PE20230301A1 (es)
PH (1) PH12022552099A1 (es)
WO (1) WO2021163438A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
MX2022012685A (es) 2020-04-10 2023-03-08 Invivyd Inc Compuestos específicos contra la proteína s de coronavirus y usos de los mismos.
US20220016268A1 (en) * 2020-07-17 2022-01-20 Tonix Pharmaceuticals Holding Corp. Skin-based testing for detection of cell-mediated immune responses to sars-cov-2
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
US20220324918A1 (en) * 2021-03-30 2022-10-13 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE ECTODOMAIN POLYPEPTIDES AND COMPOSITIONS AND METHODS THEREOF
WO2023034991A1 (en) * 2021-09-02 2023-03-09 Kansas State University Research Foundation Mrna vaccine formulations and methods of using the same
US20240385189A1 (en) * 2021-09-10 2024-11-21 Jacobs Technion-Cornell Institute Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions
KR102621026B1 (ko) * 2021-10-15 2024-01-09 에스케이바이오사이언스(주) 단백질의 정제방법
KR102527221B1 (ko) * 2021-10-15 2023-05-02 에스케이바이오사이언스 주식회사 단백질의 정제방법
KR102524839B1 (ko) * 2021-11-04 2023-04-25 에스케이바이오사이언스(주) 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
WO2023086961A1 (en) * 2021-11-12 2023-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sars-cov-2 spike fused to a hepatitis b surface antigen
US20250381265A1 (en) * 2021-12-22 2025-12-18 La Jolla Institute For Immunology Coronavirus Spike Glycoprotein With Improved Expression and Stability
CN114656571B (zh) * 2022-02-18 2024-07-16 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种四价SARS-CoV-2嵌合纳米颗粒疫苗及其制备方法与应用
KR102689037B1 (ko) * 2022-07-12 2024-07-30 에스케이바이오사이언스 주식회사 SARS-CoV-2 백신 부스터 조성물
WO2024076982A2 (en) * 2022-10-05 2024-04-11 University Of Washington Pan-sarbecovirus nanoparticle vaccines
DE202023106198U1 (de) 2022-10-28 2024-03-21 CureVac SE Impfstoff auf Nukleinsäurebasis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2173376T3 (pl) * 2007-08-02 2015-08-31 Biondvax Pharmaceuticals Ltd Multimeryczne wieloepitopowe szczepionki przeciwko grypie
US10248758B2 (en) * 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US20160376321A1 (en) * 2013-11-26 2016-12-29 Baylor College Of Medicine A novel sars immunogenic composition
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
WO2017046801A1 (en) * 2015-09-17 2017-03-23 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
WO2018175560A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
AU2018249533C1 (en) * 2017-04-04 2023-10-12 Institute For Research In Biomedicine Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
US11771755B2 (en) * 2018-02-28 2023-10-03 University Of Washington Self-asssembling nanostructure vaccines

Also Published As

Publication number Publication date
PH12022552099A1 (en) 2024-01-29
JP2023513720A (ja) 2023-04-03
CN116096404A (zh) 2023-05-09
CA3167318A1 (en) 2021-08-19
KR20220142472A (ko) 2022-10-21
WO2021163438A1 (en) 2021-08-19
EP4103230A1 (en) 2022-12-21
BR112022016220A2 (pt) 2022-10-25
CO2022011467A2 (es) 2022-10-31
AU2021221139A1 (en) 2022-09-01
US20240277831A1 (en) 2024-08-22
PE20230301A1 (es) 2023-02-13

Similar Documents

Publication Publication Date Title
PH12022552099A1 (en) Polypeptides, compositions, and their use to treat or limit development of an infection
ATE519842T1 (de) Trichoderma reesei-glucoamylase und homologe davon
SI1548032T1 (sl) KDR peptidi in cepiva, ki obsegajo le-te
BR0110927A (pt) Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
NZ596981A (en) Compositions and methods for the treatment of tumor of hematopoietic origin
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
BR9914066A (pt) Polipeptìdio degradador de c3 de complemento humano de streptococcus pneumoniae
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2021248016A3 (en) Novel omni-59, 61, 67, 76, 79, 80, 81, and 82 crispr nucleases
CA2461443A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
NZ595231A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
ATE455792T1 (de) Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
MY204432A (en) Aqueous coating composition
ATE551353T1 (de) Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten
WO2021110063A8 (en) New conjugates of peptides and polysaccharide
WO2022170216A3 (en) Omni 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, and 131-138 crispr nucleases
PH12022551990A1 (en) Diamine-linked receptor-specific cyclic peptides
CL2022002214A1 (es) Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infección
WO2022170199A3 (en) Omni-103 crispr nuclease
DK0811068T3 (da) Humane DNase I varianter
WO2022136442A3 (en) Compositions comprising cyclotides and other insecticidal peptides and uses thereof
WO2023196871A3 (en) Secretion-optimized de novo designed protein nanoparticles for eukaryotic expression and genetic delivery
ZA202401042B (en) Protein compositions for the treatment of inflammatory diseases
MX2024006722A (es) Medios y metodos para reducir la concentracion de apicidina en una composicion.